nxp900
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2023 (NCT05873686)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase YESINHIBITOR
YES1 inhibitor
- SRCINHIBITOR
SRC inhibitor
- Tyrosine-protein kinase Fyn (FYN) ↗
- Proto-oncogene tyrosine-protein kinase Src (SRC) ↗
- Tyrosine-protein kinase Lck (LCK) ↗
- Tyrosine-protein kinase Yes (YES1) ↗
- Tyrosine-protein kinase Blk (BLK) ↗
- Tyrosine-protein kinase HCK (HCK) ↗
- Tyrosine-protein kinase Lyn (LYN) ↗
- Tyrosine-protein kinase FRK (FRK) ↗
- Tyrosine-protein kinase Fgr (FGR) ↗
- Tyrosine-protein kinase Srms (SRMS) ↗
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05873686 | Phase 1 | Oct 26, 2023 | Nuvectis Pharma, Inc., Royal Marsden Hospital NHS Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1